ANI Pharmaceuticals, Inc. (ANIP)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Generics and Other	320.03M	289.31M	235.24M	-	-
Generics and Other Growth	10.62%	22.99%	-	-	-
Rare Disease and Brands	294.34M	197.50M	81.15M	-	-
Rare Disease and Brands Growth	49.03%	143.38%	-	-	-
Generics, Established Brands, and Other	-	-	-	216.14M	208.48M
Generics, Established Brands, and Other Growth	-	-	-	3.67%	0.93%
Total	614.38M	486.82M	316.39M	216.14M	208.48M
Total Growth	26.20%	53.87%	46.38%	3.67%	0.93%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
United States	604.99M	486.25M	312.43M	211.89M	202.88M
United States Growth	24.42%	55.64%	47.45%	4.44%	1.61%
Canada	9.39M	565.00K	3.96M	4.24M	5.59M
Canada Growth	1561.42%	-85.73%	-6.72%	-24.15%	-18.74%
Total	614.38M	486.82M	316.39M	216.14M	208.48M
Total Growth	26.20%	53.87%	46.38%	3.67%	0.93%

Source: S&P Global Market Intelligence.